Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Toxoid
Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Toxoid: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Toxoid.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab β 26 days.
Chemical Properties
Type: Pembrolizumab β Antibody; Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Toxoid β Vaccine component.